UNSPSC 51312901: Bufrolin

This classification denotes a mast cell stabilizer with the molecular formula C18H16N2O6, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 46C1PX266N, chemically known as 6-butyl-1,4,7,10-tetrahydro-4,10-dioxo-1,7-phenanthroline-2,8-dicarboxylic acid but generally known as bufrolin, which bears US NIH Compound Identifier 72103. European Medicines Agency schedules Bufrolin in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05966MIG. The term BUFROLIN is an International Non-Proprietary Name.

UNSPSC 51312901 Bufrolin is a Commodity code that classifies pharmaceutical products and harm-reduction supplies procured by state and local health agencies, counties, and cooperative purchasing alliances. State and local governments use this code to acquire naloxone, drug deactivation systems, generic pharmaceuticals, and over-the-counter products for community health initiatives, emergency response, and pharmacy benefit programs. Recent solicitations show demand for both specialized harm-reduction inventory (naloxone kits and safe drug disposal systems) and broader pharmaceutical supply agreements spanning multiple product lines and wholesaler networks. Issuing bodies include county health departments, state HHS commissions, and multistate cooperative purchasing alliances. The work ranges from direct equipment procurement through fixed-term contracts with quarterly delivery schedules to market-research and vendor-capability assessments prior to establishing statewide pharmacy benefit arrangements.

Activity under the code is geographically dispersed across Florida, Texas, and Minnesota, with multistate cooperative purchasing vehicles extending reach to participants including Oregon. Representative recent opportunities include Seminole County, Florida's IFB60459723LAS, posted June 30, 2026, seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries to the Seminole County Community Health Building in Sanford, Florida, with a response deadline of July 26, 2023; the Minnesota Multistate Cooperative Purchasing Alliance's Request for Proposal S1070000015802, posted January 20, 2026, establishing multiple contracts for generic multi-source pharmaceuticals and OTC products with proposals due March 26, 2026 and contract effectiveness of July 1, 2026; and the Texas Health and Human Services Commission's Request for Information HHS0017013, posted April 3, 2026, gathering vendor capabilities for a Therapeutic Pharmacy Initiative Direct-to-Manufacturer Prescriptions program with response due April 3, 2026. Vendors typically must comply with cGMP certification, Drug Supply Chain Security Act requirements, E-Verify employment verification, and insurance coverage obligations including commercial general liability and professional liability.